Download pdf
AlphaFold2-based structure prediction and target study of PD-L1 protein
- 1 University of Chinese Academy of Sciences, 19, Yuquan Road, Shijingshan District, Beijing, China (A), 100043
* Author to whom correspondence should be addressed.
Abstract
PD-L1 is an immune protein in human body that can play an important role in cancer immunotherapy. By binding to antibodies, the binding activity of PD-L1 and PD-1 is blocked, which in turn inhibits cancer cells. Thus the structure of PD-L1 is very important in studying the binding of antibodies to it. However, experimental methods to solve the structures of PD- L1 and numerous complexes are expensive and consuming. Thus, it is essential to exploit computational methods to help biologists figure out the structures and the underlying mechanisms. In this paper, we explore whether AlphaFold2 is able to accurately predict the structure of PD-L1 and whether we can use AlphaFold2 to capture the binding sites of PD-L1 when binding to different antibodies. Our results show that AlphaFold2 has high confident scores and accuracy in predicting the structure of PD-L1 and the binding sites with atezolizumab and durvalumab. For the interaction between PD-L1 and the antibodies, AlphaFold2 can capture most of the hydrogen bonds as well as the salt bridges. Our work suggests that AlphaFold2 can not only be used as a tool to predict the structure of proteins, but also serves as a useful tool for antibody discovery, e.g. providing high-quality predicted structures for downstreaming docking, which brings new hope for drug discovery.
Keywords
AlphaFold2, antibody, structure, PD-L1
[1]. Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., ... & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 18(6), 345-362
[2]. Alsaab, H. O. , †, Sau, S. , Alzhrani, R. , & Tatiparti, K. . PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
[3]. Munn, D. H. , & Bronte, V. . (2016). Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology, 39, 1-6.
[4]. Lee, H. T., Lee, S. H., & Heo, Y. S. (2019). Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules, 24(6), 1190.R.T.
[5]. Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., ... & Gao, G. F. (2016). Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein & cell, 7(12), 866-877.
[6]. Jumper,J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583-589(2021).
[7]. Thornton, J. M., Laskowski, R. A., & Borkakoti, N. (2021). AlphaFold heralds a data-driven revolution in biology and medicine. Nature Medicine, 27(10), 1666-1669.
[8]. Consortium, U. P. . (2020). Uniprot: the universal protein knowledgebase in 2021. Nucleic Acids Research(D1), D1.
[9]. Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., ... & Hassabis, D. (2021). Highly accurate protein structure prediction for the human proteome. Nature, 596(7873), 590-596.10 Mullard, A. (2021).
[10]. What does AlphaFold mean for drug discovery?. Nature reviews. Drug discovery.
[11]. Ormo, M., Cubitt, A.B., Kallio, K., Gross, L.A., Tsien, R.Y., Remington, S.J. (1996) Crystal structure of the Aequorea victoria green fluorescent protein Science 273: 1392-1395 doi: 10.1126/science.273.5280.1392
[12]. Perry, E. , Mills, J. J. , Zhao, B. , Wang, F. , Sun, Q. , & Christov, P. P. , et al. (2019). Fragment-based screening of programmed death ligand 1 (pd-l1). Bioorganic & Medicinal Chemistry Letters.
[13]. Lee, H. T. , Lee, J. Y. , Lim, H. , Lee, S. H. , Moon, Y. J. , & Pyo, H. J. , et al. (2017). Molecular mechanism of pd-1/pd-l1 blockade via anti-pd-l1 antibodies atezolizumab and durvalumab. Rep, 7(1), 5532.
[14]. Delano, W. L. . (2002). PyMOL: An Open-Source Molecular Graphics Tool.
[15]. Sebastian, S. , Sven, S. , Joachim, H. V. , Adasme, M. F. , & Michael, S. . (2015). Plip: fully automated protein–ligand interaction profiler. Nucleic Acids Research(W1), W443.
Cite this article
Yang,Z. (2023). AlphaFold2-based structure prediction and target study of PD-L1 protein. Theoretical and Natural Science,3,1-10.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).